1 2 aim
BEAMER

BEAMER

An international consortium will investigate factors affecting patient treatment adherence and develop a model to assess and understand patient needs, with the goal to provide better patient support, improve outcomes and promote further adherence.

BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe

the Innovative Medicines Initiative (IMI) announced the launch of a promising project that seeks to improve patient treatment adherence, the lack of which (non-adherence) is associated with negative patient outcomes and significant costs.

Led by Pfizer, co-led by Merck KGaA (Darmstadt, Germany) and managed by the University of Porto, the five-year project – “BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe (BEAMER)” – brings together 28 European partners from academia, civil society and industry to jointly address this goal.

Patient non-adherence to prescribed treatment poses a formidable health challenge. It affects patient health outcomes significantly, contributing to 200,000 premature deaths in the EU annually, and places a heavy economic burden on the healthcare system, leading to an estimated 125B euros in avoidable hospitalisations, emergency care and adult outpatient visits each year.

Despite existing research on disease-specific treatment adherence, there are few broad insights regarding how to improve adherence across healthcare. To address this, BEAMER aims to acquire a comprehensive understanding of the factors that influence patient adherence, irrespective of the therapeutic area, and enable stakeholders to design effective solutions that could promote broad and consistent impact within a real-world context.

BEAMER collaborations

Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA], and associated partner Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.